Dyadic International, using its C1 gene expression platform, is developing recombinant vaccines and neutralizing agents comprising targeted antigens, monoclonal antibodies, biosimilars/biobetters, and therapeutic proteins. The programme is at early research phase of development in Israel.
Dyadic International in collaboration with the Israel Institute for Biological Research are developing an rVaccine candidate and monoclonal antibodies (mAbs) against COVID-2019 infections, using the proven C1 gene expression platform.
Earlier, Dyadic Nederland B.V (a subsidiary of Dyadic International), and EnGen Bio were collaborating on a research programme to develop significant protein production based on Thermothelomyces heterothallica (formerly Myceliophthora thermophila), using Dyadic's proprietary and patented C1 platform technology, for undisclosed indications. Upon successful completion of proof of concept studies Sanofi had option rights to the C1 technology for its vaccine application. Early research was underway in the Netherlands. However, in August 2016, Sanofi terminated its agreement with Dyadic and development was discontinued.
In February 2020, Dyadic International expanded the collaboration with the Israel Institute for Biological Research, against COVID-2019 infections. IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus). Earlier, in January 2018, Dyadic International had entered into a research and development collaboration with the Israel Institute for Biological Research (IIBR), wherein the former will progress its C1 expression platform for the development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies, to combat emerging diseases and threats. The work will be performed at IIBR’s laboratories.  
In February 2018, Dyadic International entered into a funded proof of concept research collaboration to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications with Mitsubishi Tanabe Pharma Corporation. 
In July 2017, Dyadic International entered into a research and development agreement with VLP The Vaccines Company, so as to leverage the BDI team’s know-how in the development of next generation vaccines and drugs. Additionally, Dyadic will utilize BDI’s previous C1 industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology for biopharmaceutical product development and production. Dyadic engaged BDI to provide research and development services for an aggregate of approximately US$2.1 million over two years, including €1 million through a Research Services Agreement to develop designated C1 based product candidates and another US$1 million through a Service Framework Agreement for certain research projects specified by Dyadic. All of the data and any products developed from the funded research projects will be owned by Dyadic. As part of these research agreements, Dyadic received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. 
In August 2016, Dyadic received 60-day notice from Sanofi for the termination of Proof-of-concept, exclusive option and technology transfer agreement. In October 2016, the effective termination date of the agreement, Sanofi’s prior option rights to the C1 technology previously covered by the agreement will be reverted back to Dyadic. Upon such reversion, Dyadic expects to leverage the knowledge gained, and the progress made from the meaningful improvements to the C1 expression system across all biologic vaccine and drug indications  . Dyadic and Sanofi Pasteur entered into a research collaboration to develop vaccine in May 2011. Under the agreement, Sanofi is funding the research, which will be conducted under the guidance of Dyadic, coordinated by EnGen Bio. Dyadic's C1 technology uses patented strains of the fungus Myceliopthora thermophila (formerly known as Chrysosporium lucknowense) (C1) to discover and express both eukaryotic and prokaryotic genes. EnGen Bio uses a novel manufacturing system to generate biologics and vaccines  .
Key Development Milestones
As of February 2020, Dyadic International in collaboration with the Israel Institute for Biological Research are developing an rVaccine candidate and monoclonal antibodies (mAbs) against COVID-2019 infections  .